This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
CSW, ASAN, and others show rising P/E trends -- suggesting breakout potential backed by strong earnings surprises.
LifeStance Health (LFST) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging 9.9% in 4 Weeks, Here's Why the Trend Might Reverse for LifeStance Health (LFST)
by Zacks Equity Research
The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 45.04%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -20.26% in 4 Weeks, Here's Why LifeStance Health (LFST) Looks Ripe for a Turnaround
by Zacks Equity Research
LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q1
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 100% and 0.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe LifeStance Health (LFST) Could Rally 28.68%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for LifeStance Health (LFST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Surges 4.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Addus HomeCare (ADUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LifeStance Health (LFST) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 26.63% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for LifeStance Health (LFST) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LifeStance Health (LFST) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 50% and 4.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs
by Zacks Equity Research
MOH expects total membership to be at 5.9 million by 2025-end.
New Strong Buy Stocks for January 29th
by Zacks Equity Research
MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024.
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV's fourth-quarter results benefit from rising premiums. However, higher expenses and attrition in Medicaid membership partially offset the positives.
Here's Why You Should Add Ensign Stock to Your Portfolio Now
by Zacks Equity Research
ENSG's valuation looks relatively cheap compared with the industry average.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Mixed Bag for UnitedHealth: Q4 Earnings Beat, Revenues Fall Short
by Zacks Equity Research
UNH projects revenues between $450 billion and $455 billion for 2025.
LifeStance Health Group (LFST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 71.43% and 3.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -12.28% and 0.08%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy (ATIP) delivered earnings and revenue surprises of -56.73% and 3.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?